Literature DB >> 12541035

Laparoscopic cholecystectomy for acute cholecystitis.

Seigo Kitano1, Toshifumi Matsumoto, Masaori Aramaki, Katsunori Kawano.   

Abstract

The application of laparoscopic cholecystectomy (Lap. C) for acute cholecystitis (AC) remains controversial from the viewpoint of its higher rate of morbidity, and conversion to open surgery, in spite of the worldwide acceptance of Lap. C as the gold standard for the treatment of patients with symptomatic gallbladder diseases. The conversion rate has been reported to decrease with experience. Local and overall complication rates were shown to correlate with the time delay between the onset of acute symptoms and the operation. Although percutaneous gallbladder drainage (PGBD) has been reported to be a safe and effective procedure for the treatment of AC, it should be limited to high-risk groups such as elderly or critically ill patients. Early cholecystectomy within 4 days from the onset is strongly recommended to minimize surgical complications and to increase the chance of a successful laparoscopic approach.

Entities:  

Mesh:

Year:  2002        PMID: 12541035     DOI: 10.1007/s005340200069

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  10 in total

1.  Profiling hospital performance of laparoscopic cholecystectomy based on the administrative data of four teaching hospitals in Japan.

Authors:  Masahiro Hirose; Yuichi Imanaka; Tatsuro Ishizaki; Miho Sekimoto; Yoshiaki Harada; Kazuaki Kuwabara; Kenshi Hayashida; Eun-Hwan Oh; S Edward Evans
Journal:  World J Surg       Date:  2005-04       Impact factor: 3.352

2.  Delay from symptom onset increases the conversion rate in laparoscopic cholecystectomy for acute cholecystitis.

Authors:  Sirwan M Hadad; Jayant S Vaidya; Lee Baker; Hoey C Koh; Timothy P Heron; Kashif Hussain; Alastair M Thompson
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.352

3.  Laparoscopic subtotal cholecystectomy as an alternative procedure designed to prevent bile duct injury: experience of a hospital in northern China.

Authors:  Yu Tian; Shuo-Dong Wu; Yang Su; Jing Kong; Hong Yu; Ying Fan
Journal:  Surg Today       Date:  2009-05-27       Impact factor: 2.549

4.  Laparoscopic cholecystectomy for acute cholecystitis: safe implementation of successful strategies to reduce conversion rates.

Authors:  Shiong-Wen Low; Shridhar Ganpathi Iyer; Stephen K-Y Chang; Kenneth S W Mak; Victor Tswen Wen Lee; Krishnakumar Madhavan
Journal:  Surg Endosc       Date:  2009-03-05       Impact factor: 4.584

5.  Risk-adjusted treatment selection and outcome of patients with acute cholecystitis.

Authors:  J I González-Muñoz; G Franch-Arcas; M Angoso-Clavijo; M Sánchez-Hernández; A García-Plaza; M Caraballo-Angeli; L Muñoz-Bellvís
Journal:  Langenbecks Arch Surg       Date:  2016-10-04       Impact factor: 3.445

6.  Treatment of gallbladder disease during operations Iraqi Freedom and Enduring Freedom.

Authors:  Chad R Edwards; James P Dolan; Raymond Fang; Richard E Standaert
Journal:  Surg Endosc       Date:  2009-07-08       Impact factor: 4.584

7.  Nondrainage after Laparoscopic Cholecystectomy for Acute Calculous Cholecystitis Does Not Increase the Postoperative Morbidity.

Authors:  Jianguo Qiu; Ming Li
Journal:  Biomed Res Int       Date:  2018-07-02       Impact factor: 3.411

8.  Health-Related Quality of Life After Laparoscopic Cholecystectomy.

Authors:  Qurrat Al Ain Atif; Mumtaz A Khan; Faisal Nadeem; Muneeb Ullah
Journal:  Cureus       Date:  2022-07-11

9.  Cholecystomucoclasis: revaluation of safety and validity in aged populations.

Authors:  Tomoya Tsukada; Tatsuo Nakano; Takashi Miyata; Shozo Sasaki; Tetsuo Ohta
Journal:  BMC Gastroenterol       Date:  2012-08-21       Impact factor: 3.067

10.  Operative timing of laparoscopic cholecystectomy for acute cholecystitis in a Japanese institute.

Authors:  Masayuki Ohta; Yukio Iwashita; Kazuhiro Yada; Tadashi Ogawa; Seiichiro Kai; Tetsuya Ishio; Kohei Shibata; Toshifumi Matsumoto; Toshio Bandoh; Seigo Kitano
Journal:  JSLS       Date:  2012 Jan-Mar       Impact factor: 2.172

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.